Joe McCann is a seasoned biotech leader with nearly two decades of experience across start-ups and global pharma, specializing in targeted radiotherapies for oncology. Dr. McCann brings deep expertise in clinical development, CMC, supply chain, and manufacturing strategies. Joe co-founded POINT Biopharma Inc. in 2019, leading it from inception through a successful NASDAQ listing in 2021 and a $1.4B acquisition by Eli Lilly in 2023. Under his leadership, POINT advanced multiple assets through clinical development, built first-of-its-kind manufacturing infrastructure, and secured over $650M in financing. Joe played a pivotal role in integrating POINT’s platform and pipeline into Lilly’s oncology division.
Previously, Joe served as CEO of the Centre for Probe Development and Commercialization (CPDC), a supply chain pioneer in radioligand therapy and imaging products. During his tenure, Joe created the CDMO division, now known as AtomVie Global Radiopharma. He began his career at GlaxoSmithKline in Pharmaceutical Development.
Joe holds a Ph.D. in Biochemistry from McMaster University and a B.Sc. in Biochemistry from the University of Guelph. He now advises companies and investors in theranostics, CDMO strategy, and supply chain innovation.